ANTIEPILEPTIC DRUGS MARKET ANALYSIS

Regional Analysis

Global Antiepileptic Drugs Market- Regional Analysis

Among region, North America is estimated to hold a dominant position in the global antiepileptic drugs market over the forecast period. North America is estimated to hold 37.7% of the market share in 2023. North America antiepileptic drugs market is expected to witness significant growth in the near future, owing to approval of new drugs in the market. For instance, in August 2021, UCB S.A, a global pharmaceutical firm, announced that the U.S. FDA had approved an extended indication for BRIVIACT (brivaracetam) CV tablets, oral solution, and injection to treat partial-onset seizures in infants as young as one month old. This is the first time that the IV formulation of BRIVIACT will be available for pediatric patients when oral administration is temporarily not possible, and it is the only IV formulation U.S. FDA approved to treat partial-onset seizures in children one month and older or  nearly 7 years.

• North America: U.S. and Canada
• Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
• Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
• Middle East: GCC, Israel, and Rest of Middle East
• Africa: South Africa, North Africa, and Central Africa